TSH Biopharm (ROCO:8432) Cyclically Adjusted FCF per Share: NT$2.50 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
89 GF Score
Price NT$49.65
GF Value NT$74.84
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is TSH Biopharm Cyclically Adjusted FCF per Share?

TSH Biopharm ROCO:8432 +1.74% 89 Cyclically Adjusted FCF per Share is NT$2.50 as of Mar. 2026. GuruFocus rates ROCO:8432 with a GF Score™ of 89/100 and a GF Value™ of NT$74.84 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

TSH Biopharm's adjusted free cash flow per share for the three months ended in Mar. 2026 was NT$4.229. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$2.50 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TSH Biopharm's average Cyclically Adjusted FCF Growth Rate was 29.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of TSH Biopharm was 13.70% per year. The lowest was 0.80% per year. And the median was 1.80% per year.

As of today (2026-07-31), TSH Biopharm's current stock price is NT$49.65. TSH Biopharm's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was NT$2.50. TSH Biopharm's Cyclically Adjusted Price-to-FCF of today is 19.86.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TSH Biopharm was 41.31. The lowest was 18.61. And the median was 28.28.


TSH Biopharm  (ROCO:8432) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

TSH Biopharm's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=49.65/2.50
=19.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TSH Biopharm was 41.31. The lowest was 18.61. And the median was 28.28.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


TSH Biopharm Cyclically Adjusted FCF per Share Related Terms


TSH Biopharm Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Cyclically Adjusted FCF per Share Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 1.95 1.70 1.94 2.06

TSH Biopharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 1.93 1.98 2.06 2.50

ROCO:8432 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TSH Biopharm Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TSH Biopharm's Cyclically Adjusted Price-to-FCF falls into.


ROCO:8432
89GF Score
TSH Biopharm Corp Ltd ROCO:8432
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TSH Biopharm's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.229/330.2130*330.2130
=4.229

Current CPI (Mar. 2026) = 330.2130.

TSH Biopharm Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 1.149 241.018 1.574
201609 -0.118 241.428 -0.161
201612 -0.114 241.432 -0.156
201703 0.262 243.801 0.355
201706 0.971 244.955 1.309
201709 0.838 246.819 1.121
201712 -0.086 246.524 -0.115
201803 0.432 249.554 0.572
201806 0.656 251.989 0.860
201809 -0.006 252.439 -0.008
201812 0.386 251.233 0.507
201903 0.280 254.202 0.364
201906 0.526 256.143 0.678
201909 1.312 256.759 1.687
201912 0.100 256.974 0.129
202003 -0.721 258.115 -0.922
202006 0.475 257.797 0.608
202009 0.356 260.280 0.452
202012 0.125 260.474 0.158
202103 0.517 264.877 0.645
202106 0.590 271.696 0.717
202109 0.430 274.310 0.518
202112 0.259 278.802 0.307
202203 -0.219 287.504 -0.252
202206 0.823 296.311 0.917
202209 0.471 296.808 0.524
202212 -0.678 296.797 -0.754
202303 -0.140 301.836 -0.153
202306 0.748 305.109 0.810
202309 -0.309 307.789 -0.332
202312 0.444 306.746 0.478
202403 1.385 312.332 1.464
202406 0.409 314.175 0.430
202409 0.933 315.301 0.977
202412 1.968 315.605 2.059
202503 0.548 319.799 0.566
202506 1.019 322.561 1.043
202509 0.773 324.800 0.786
202512 1.016 324.054 1.035
202603 4.229 330.213 4.229

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$2.50 mean?
TSH Biopharm (ROCO:8432) has a Cyclically Adjusted FCF per Share of NT$2.50 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on TSH Biopharm and its competitors.
Is TSH Biopharm's Cyclically Adjusted FCF per Share too high?
TSH Biopharm's current Cyclically Adjusted FCF per Share is NT$2.50. Overall, TSH Biopharm has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Cyclically Adjusted FCF per Share compare to ZTS?
TSH Biopharm's Cyclically Adjusted FCF per Share of NT$2.50 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on TSH Biopharm and its competitors. TSH Biopharm's current Cyclically Adjusted FCF per Share is NT$2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.84, compared to a current price of NT$49.65 — trading 33.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$2.50. TSH Biopharm's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Cyclically Adjusted FCF per Share is NT$2.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$49.65 is trading 33.7% below its estimated GF Value™ of NT$74.84. GuruFocus considers TSH Biopharm to be Significantly Undervalued.

Key valuation signals for ROCO:8432:

  • Cyclically Adjusted FCF per Share: NT$2.50
  • GF Value™: NT$74.84 vs. price of NT$49.65 (33.7% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
89GF Score

Get the complete analysis for ROCO:8432

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.65
Price
NT$74.84
GF Value